Annovis Alzheimer’s Program Sees Strong Phase 3 Progress
All 84 U.S. sites are active for Annovis Bio’s pivotal Phase 3 Alzheimer’s program, with the first participants reaching...
Promising Barzolvolimab Data Shows Complete Urticaria Control
Celldex’s barzolvolimab delivered a mean UCT7 improvement of up to 8.6 points versus 2.5 for placebo at Week 12...
Avance Unveils Special CNS Center for Neuroscience Trials
Screen failure rates average 57% in CNS studies, compared with 36.3% across other therapeutic areas, and Avance Clinical points...
Quoin Netherton Syndrome Study Shows Positive 9-Month Data
In an investigator-led pediatric study of QRX003 for Netherton syndrome, the first enrolled child achieved complete skin clearance by...
Hutchmed Completes Enrollment for Saffron Lung Cancer Trial
HUTCHMED and AstraZeneca completed randomization of 338 patients in SAFFRON, a global, open-label Phase III comparing all-oral savolitinib plus...
Mesoblast to Meet FDA on Rexlemestrocel-L for Opioid Use
In a randomized Phase 3 study of 404 patients with discogenic chronic low back pain, including 168 on opioids...
Spyre’s SPY003 Antibody Shows Positive Phase 1 Results
In a first-in-human Phase 1 study in healthy volunteers (n=59), Spyre Therapeutics’ extended half-life anti-IL-23 antibody SPY003 was well...
Lisata Touts Surprising Preclinical Certepetide ADC Data
Preclinical data presented at the World ADC San Diego meeting show that incorporating Lisata’s iRGD cyclic peptide, certepetide, as...
Hengrui/Kailera Phase 3 Obesity Trial Data Revealed in China
Hengrui’s once-weekly dual GLP-1/GIP agonist HRS9531 delivered 48-week mean weight loss of 11.2%, 17.4%, and 19.2% at 2 mg,...
Aardvark’s New Obesity Pipeline Data Offers Surprising Hope
In preclinical diet-induced obesity models, Aardvark’s fixed-dose candidate ARD-201 reduced body weight by roughly 19% over 30 days, comparable...